Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru

View ORCID ProfilePercy Soto-Becerra, View ORCID ProfileCarlos Culquichicón, View ORCID ProfileYamilee Hurtado-Roca, View ORCID ProfileRoger V. Araujo-Castillo
doi: https://doi.org/10.1101/2020.10.06.20208066
Percy Soto-Becerra
1Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud Jiron Domingo Cueto 120, Eight floor, Jesus Maria, Lima 15073, Peru
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Percy Soto-Becerra
Carlos Culquichicón
1Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud Jiron Domingo Cueto 120, Eight floor, Jesus Maria, Lima 15073, Peru
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos Culquichicón
Yamilee Hurtado-Roca
1Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud Jiron Domingo Cueto 120, Eight floor, Jesus Maria, Lima 15073, Peru
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yamilee Hurtado-Roca
Roger V. Araujo-Castillo
1Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud Jiron Domingo Cueto 120, Eight floor, Jesus Maria, Lima 15073, Peru
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roger V. Araujo-Castillo
  • For correspondence: roger.araujo@essalud.gob.pe
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Introduction Peru is one of the most impacted countries due to COVID-19. Given the authorized use of hydroxychloroquine (HCQ), azithromycin (AZIT), and ivermectin (IVM), we aimed to evaluate their effectiveness alone or combined to reduce mortality among COVID-19 hospitalized patients without life-threatening illness.

Methods Retrospective cohort emulating a target trial, using nationwide data of mid- and high-level hospitals from the Peruvian Social Health Insurance 01/April/2020–19/July/2020. Patients 18 yo and above with PCR-confirmed SARS-CoV-2, and no life-threatening illness at admission were included. Five treatment groups (HCQ alone, IVM alone, AZIT alone, HCQ+AZIT, and IVM+AZIT within 48 hours of admission) were compared with standard of care alone. Primary outcome was all-cause mortality rate; secondary outcomes were all-cause death and/or ICU transfer, and all-cause death and/or oxygen prescription. Analyses were adjusted using inverse probability of treatment weighting. Propensity scores were estimated using machine learning boosting models. Weighted hazard ratios (wHR) were calculated using Cox regression.

Results Among 5683 patients, 200 received HCT, 203 IVM, 1600 AZIT, 692 HCQ+AZIT, 358 IVM+AZIT, and 2630 standard of care. HCQ+AZIT was associated with 84% higher all-cause death hazard compared to standard care (wHR=1.84, 95%CI 1.12-3.02). Consistently, HCQ+AZIT was also associated with higher death and/or ICU transfer (wHR=1.49, 95%CI 1.01-2.19), and death and/or oxygen prescription (wHR=1.70, 95%CI 1.07-2.69). HCQ only showed higher death and/or oxygen prescription hazard. No effect was found for AZIT or IVM+AZIT.

Conclusions Our study reported no beneficial effects of hydroxychloroquine, ivermectin, azithromycin. The HCQ+AZIT treatment seems to increase risk for all-cause death.

Funding Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Instituto de Evaluacion de Tecnologias en Salud e Investigacion (IETSI), EsSalud, Peru.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was classified with minimal risk of vulnerability for participants. In order to maintain the privacy of the patients, the data extraction was anonymized by the EsSalud informatics office before data manipulation or analysis. This target trial protocol was approved by EsSalud Institutional Review Board of COVID studies (91-SGRyGIS-DIS-IETSI-ESSALUD-2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Writing and wording of Introduction, Methods, Results and Discussion were updated to clarify reporting. Typos in table and in Methods (propensity score weighting calculation) were corrected. Figure 2 and 3 were edited to improve visualization. similarly, figures of Supplementary material were edited to improve visualization.

Data Availability

The data supporting the findings of this study are available in the IETSI EsSalud computer files, but restrictions apply to the availability of these data, which were used under the current study license and are therefore not publicly available. However, the data are available to the authors upon reasonable request and with the permission of IETSI EsSalud.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 14, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
Percy Soto-Becerra, Carlos Culquichicón, Yamilee Hurtado-Roca, Roger V. Araujo-Castillo
medRxiv 2020.10.06.20208066; doi: https://doi.org/10.1101/2020.10.06.20208066
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
Percy Soto-Becerra, Carlos Culquichicón, Yamilee Hurtado-Roca, Roger V. Araujo-Castillo
medRxiv 2020.10.06.20208066; doi: https://doi.org/10.1101/2020.10.06.20208066

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (432)
  • Anesthesia (99)
  • Cardiovascular Medicine (946)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8977)
  • Forensic Medicine (4)
  • Gastroenterology (419)
  • Genetic and Genomic Medicine (1943)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1324)
  • Health Policy (657)
  • Health Systems and Quality Improvement (518)
  • Hematology (212)
  • HIV/AIDS (417)
  • Infectious Diseases (except HIV/AIDS) (10787)
  • Intensive Care and Critical Care Medicine (574)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1822)
  • Nursing (109)
  • Nutrition (271)
  • Obstetrics and Gynecology (352)
  • Occupational and Environmental Health (470)
  • Oncology (996)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (578)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1894)
  • Public and Global Health (4117)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (365)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)